Hetao Huang1, Minghui Luo2, Haodong Liang3, Jianke Pan2, Weiyi Yang2, Lingfeng Zeng2, Guihong Liang2, Senrong Hou1, Jinlong Zhao1, Jun Liu2. 1. Second School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China. 2. Department of Orthopaedics, Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China. 3. Guangzhou Hospital of Traditional Chinese Medicine, Guangzhou, China.
Abstract
OBJECTIVE: To compare the efficacy and safety of celecoxib and diclofenac sodium in patients with knee osteoarthritis (KOA). METHODS: Clinical controlled trials (CCTs) and randomized controlled trials (RCTs) from online databases comparing the efficacy of celecoxib and diclofenac sodium in the treatment of KOA were retrieved. The main outcomes included the treatment effect, C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), visual analog scale (VAS) score, and complication rate. The Cochrane risk of bias (ROB) tool in Review Manager 5.3.5 was used to assess methodological quality. RESULTS: Twelve studies (N = 2,350) were included in this meta-analysis. The meta-analysis indicated that celecoxib reduced pain more effectively than diclofenac sodium in patients with KOA, as evaluated by the VAS score. In addition, celecoxib has certain advantages in terms of better treatment effects and greater reductions in the ESR, CRP level, and complication rate. CONCLUSIONS: Celecoxib is superior to diclofenac sodium in the treatment of KOA. However, well-designed and high-quality RCTs are still needed.
OBJECTIVE: To compare the efficacy and safety of celecoxib and diclofenac sodium in patients with knee osteoarthritis (KOA). METHODS: Clinical controlled trials (CCTs) and randomized controlled trials (RCTs) from online databases comparing the efficacy of celecoxib and diclofenac sodium in the treatment of KOA were retrieved. The main outcomes included the treatment effect, C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), visual analog scale (VAS) score, and complication rate. The Cochrane risk of bias (ROB) tool in Review Manager 5.3.5 was used to assess methodological quality. RESULTS: Twelve studies (N = 2,350) were included in this meta-analysis. The meta-analysis indicated that celecoxib reduced pain more effectively than diclofenac sodium in patients with KOA, as evaluated by the VAS score. In addition, celecoxib has certain advantages in terms of better treatment effects and greater reductions in the ESR, CRP level, and complication rate. CONCLUSIONS: Celecoxib is superior to diclofenac sodium in the treatment of KOA. However, well-designed and high-quality RCTs are still needed.
Authors: Ian J Wallace; Steven Worthington; David T Felson; Robert D Jurmain; Kimberly T Wren; Heli Maijanen; Robert J Woods; Daniel E Lieberman Journal: Proc Natl Acad Sci U S A Date: 2017-08-14 Impact factor: 11.205
Authors: Nicola Veronese; Cyrus Cooper; Olivier Bruyère; Nasser M Al-Daghri; Jaime Branco; Etienne Cavalier; Sara Cheleschi; Mario Coelho da Silva Rosa; Philip G Conaghan; Elaine M Dennison; Maarten de Wit; Antonella Fioravanti; Nicholas R Fuggle; Ida K Haugen; Gabriel Herrero-Beaumont; Germain Honvo; Andrea Laslop; Radmila Matijevic; Alberto Migliore; Ali Mobasheri; Jean-Pierre Pelletier; María Concepción Prieto Yerro; Régis Pierre Radermecker; François Rannou; René Rizzoli; Jean-Yves Reginster Journal: Drugs Date: 2022-09-16 Impact factor: 11.431